JP2024532853A - 治療用パピローマウイルスワクチン - Google Patents

治療用パピローマウイルスワクチン Download PDF

Info

Publication number
JP2024532853A
JP2024532853A JP2024510296A JP2024510296A JP2024532853A JP 2024532853 A JP2024532853 A JP 2024532853A JP 2024510296 A JP2024510296 A JP 2024510296A JP 2024510296 A JP2024510296 A JP 2024510296A JP 2024532853 A JP2024532853 A JP 2024532853A
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
vector
cell
papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532853A5 (enExample
Inventor
ティリオン，クリスティアン
ペルトゥル，コルドゥラ
カルラス，アレクサンダー
ザンディヒ，フォルカー
ヨルダン，インゴ
ヨハネス ホルスト，ペーター
ボイレセン，ディッテ ラーベク
ヴァーグナー，ラルフ
ネッカーマン，パトリック
アスバッハ，ベネディクト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProBioGen AG
InProTher ApS
Original Assignee
ProBioGen AG
InProTher ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProBioGen AG, InProTher ApS filed Critical ProBioGen AG
Publication of JP2024532853A publication Critical patent/JP2024532853A/ja
Publication of JP2024532853A5 publication Critical patent/JP2024532853A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024510296A 2021-08-18 2022-08-17 治療用パピローマウイルスワクチン Pending JP2024532853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21191940.2 2021-08-18
EP21191940.2A EP4137153A1 (en) 2021-08-18 2021-08-18 Therapeutic papilloma virus vaccines
PCT/EP2022/073016 WO2023021116A1 (en) 2021-08-18 2022-08-17 Therapeutic papilloma virus vaccines

Publications (2)

Publication Number Publication Date
JP2024532853A true JP2024532853A (ja) 2024-09-10
JP2024532853A5 JP2024532853A5 (enExample) 2025-09-12

Family

ID=77398487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510296A Pending JP2024532853A (ja) 2021-08-18 2022-08-17 治療用パピローマウイルスワクチン

Country Status (9)

Country Link
US (1) US20250066427A1 (enExample)
EP (2) EP4137153A1 (enExample)
JP (1) JP2024532853A (enExample)
KR (1) KR20240095168A (enExample)
CN (1) CN117940156A (enExample)
AU (1) AU2022331111A1 (enExample)
CA (1) CA3229203A1 (enExample)
MX (1) MX2024002010A (enExample)
WO (1) WO2023021116A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026523389A (ja) * 2023-05-26 2026-07-14 プロバイオジェン アーゲー 二倍体組換え核細胞質大型ｄｎａウイルスベクター
CN120607593A (zh) * 2024-03-06 2025-09-09 诺未生物技术(无锡)有限公司 治疗hpv感染相关疾病的药物
CN119569831B (zh) * 2024-12-13 2026-04-28 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用
CN122405672A (zh) * 2025-01-10 2026-07-17 成都迈科康生物科技股份有限公司 一种rna疫苗及其相关产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007054074A (ja) * 1995-07-27 2007-03-08 Csl Ltd パピローマウイルスのポリプロテイン構築物
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
JP2019514943A (ja) * 2016-05-02 2019-06-06 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖワクチン組み合わせ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
SI1957528T1 (sl) 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
SI2865387T1 (sl) 2008-11-21 2019-10-30 Kobenhavns Univ University Of Copenhagen Primiranje imunskega odziva
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
US12576143B2 (en) 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007054074A (ja) * 1995-07-27 2007-03-08 Csl Ltd パピローマウイルスのポリプロテイン構築物
JP2019514943A (ja) * 2016-05-02 2019-06-06 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖワクチン組み合わせ
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B G WIEKING ET AL., CANCER GENE THERAPY, vol. 19, JPN7026002906, 2012, pages 667 - 674, ISSN: 0005897744 *
C EDMONDS ET AL., JOURNAL OF VIROLOGY, vol. 63, JPN7026002908, 1989, pages 2650 - 2656, ISSN: 0005897746 *
CHRISTELLE REMY-ZILLER ET AL., CLINICAL AND VACCINE IMMUNOLOGY, vol. 21, JPN7026002905, 2014, pages 147 - 155, ISSN: 0005897743 *
E RAGONNAUD ET AL., SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 85, JPN7026002904, 2017, pages 182 - 190, ISSN: 0005897742 *
EMELINE RAGONNAUD ET AL., VACCINE, vol. 36, JPN7026002903, 2018, pages 6212 - 6222, ISSN: 0005897741 *
JANET L BRANDSMA ET AL., JOURNAL OF VIROLOGY, vol. 81, JPN7026002902, 2007, pages 5749 - 5758, ISSN: 0005897740 *
SHIWEN PENG ET AL., MBIO, vol. 12, JPN7026002907, 19 January 2021 (2021-01-19), pages 03224 - 20, ISSN: 0005897745 *

Also Published As

Publication number Publication date
MX2024002010A (es) 2024-04-18
EP4387662A1 (en) 2024-06-26
EP4137153A1 (en) 2023-02-22
CA3229203A1 (en) 2023-02-23
AU2022331111A1 (en) 2024-03-07
WO2023021116A1 (en) 2023-02-23
US20250066427A1 (en) 2025-02-27
KR20240095168A (ko) 2024-06-25
CN117940156A (zh) 2024-04-26

Similar Documents

Publication Publication Date Title
AU2021232660B2 (en) HPV vaccines
US20250066427A1 (en) Therapeutic papilloma virus vaccines
JP6606571B2 (ja) 治療用ｈｐｖ１６ワクチン
He et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
TWI744246B (zh) 治療性hpv18疫苗
US11466292B2 (en) Compositions and methods of treatment
KR20210050558A (ko) 질환의 예방 및/또는 치료에 사용하기 위한 백신
JP2020527029A (ja) Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
CA2890061A1 (en) Conditional replicating viral vectors
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
Boilesen et al. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice
Neckermann et al. Design and immunological validation of macaca fascicularis papillomavirus type 3 based vaccine candidates in outbred mice: basis for future testing of a therapeutic papillomavirus vaccine in NHPs
Neckermann Design and Characterization of Vaccine Candidates for Therapeutic Vaccination Against Papillomaviruses
Illiano et al. Prime–boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the human papilloma virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X
TW202519538A (zh) 基於ｃｍｖ之人類乳頭瘤病毒疫苗
Bissa Construction and evaluation of recombinant immunogens as therapeutic vaccines against HPV-related cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250815

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630